Ravi Amaravadi, MD

Amaravadi is a melanoma specialist and Associate Director, Translational Research, at Penn Medicine’s Abramson Cancer Center.

Articles by Ravi Amaravadi, MD

Streamlining the TIL Therapy Pipeline for Melanoma

ByRavi Amaravadi, MD

May 28th 2026

Ravi Amaravadi, MD, discusses how his team approaches tumor-infiltrating lymphocyte therapy to avoid delays that could keep patients from getting treated.

Ravi Amaravadi, MD

Articles by Ravi Amaravadi, MD

Streamlining the TIL Therapy Pipeline for Melanoma

Latest Updated Articles

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Sac-TMT Plus Pembrolizumab Beats Chemo-Immunotherapy in PD-L1–Negative NSCLC

FDA Approves Gedatolisib for HR+/HER2−, PIK3CA Wild-Type Advanced Breast Cancer

Phase 3 Trial Initiated for Rinzimetostat Plus Darolutamide in mCRPC

Pembro Monotherapy Boosts PFS Vs Chemo in dMMR Endometrial Cancer

Advanced Renal Cell Carcinoma: Summarizing a Practical First-Line Treatment Algorithm